Skip to main content
. 2017 Apr 27;2017:7065759. doi: 10.1155/2017/7065759

Figure 5.

Figure 5

Sorafenib inhibits multiple tyrosine kinase and second messenger pathways. In the cardiac myocyte, inhibition of prosurvival pathways RAS/MAPK via BRAF and P13K/AKT1 via VEGFR leads to diminished survival. Sorafenib further inhibits RAF1, which leads to loss of tonic inhibition of cell death pathways and death through activation of caspases.